Last $4.99 USD
Change Today -0.08 / -1.58%
Volume 31.7K
ALQA On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 3:32 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

alliqua biomedical inc (ALQA) Snapshot

Open
$4.97
Previous Close
$5.07
Day High
$5.11
Day Low
$4.91
52 Week High
01/28/14 - $9.50
52 Week Low
10/28/14 - $3.70
Market Cap
80.7M
Average Volume 10 Days
81.0K
EPS TTM
$-2.53
Shares Outstanding
16.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALLIQUA BIOMEDICAL INC (ALQA)

Related News

No related news articles were found.

alliqua biomedical inc (ALQA) Related Businessweek News

No Related Businessweek News Found

alliqua biomedical inc (ALQA) Details

Alliqua, Inc., a biomedical company, focuses on the development, manufacture, and distribution of proprietary transdermal wound care and drug delivery technologies. The company provides water content, electron beam cross-linked, and aqueous polymer hydrogels for use in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. Its products include SilverSeal, a hydrogel wound dressing with silver coated fibers; and Hydress, an over-the-counter hydrogel wound dressing. The company also develops HepaMate, an extracorporeal temporary liver support system designed to provide whole liver function to patients with acute or severe liver failure. It has a license, marketing, and development agreement with Anthrogenesis Corporation for the development and commercialization of Extracellular Matrix and Biovance products. Alliqua, Inc. is headquartered in Langhorne, Pennsylvania.

21 Employees
Last Reported Date: 03/24/14

alliqua biomedical inc (ALQA) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $483.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $96.7K
Compensation as of Fiscal Year 2013.

alliqua biomedical inc (ALQA) Key Developments

Alliqua BioMedical, Inc. and Premier, Inc. Sign Group Purchasing Agreement for Skin Grafting Products

Alliqua BioMedical, Inc. has signed a group purchasing agreement with Premier, Inc. for skin grafting products. This agreement offers Premier alliance members access to Alliqua BioMedical's regenerative skin graft products, including Biovance Human Amniotic Membrane Allograft, at specially negotiated pricing and terms.

Alliqua Biomedical, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Full Year of 2014 and 2015

Alliqua BioMedical, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $1,493,840 compared to $437,985 last year. Loss from operations was $5,157,715 compared to $2,265,762 last year. Loss before income tax provision was $5,099,943 compared to $2,233,045 reported a year ago. Net loss was $5,103,443 or $0.33 per basic and diluted share compared to a loss of $2,236,045 or $0.31 per basic and diluted share for the same period last year. Total revenue growth year-over-year was driven by a 1,445% increase in sales of proprietary products and a 34% increase in contract manufacturing sales compared to last year. For the nine months, the company total revenue of $3,121,863 compared to $1,328,911 last year. Loss from operations was $20,086,381 compared to $6,773,516 last year. Loss before income tax provision was $20,083,334 compared to $7,020,224 reported a year ago. Net loss was $20,093,834 or $1.41 per basic and diluted share compared to a loss of $7,029,224 or $1.09 per basic and diluted share for the same period last year. Total revenue growth was driven by a 2,172% increase in sales of proprietary products - Sorbion, Biovance and Therabond - and a 17% increase in contract manufacturing revenues compared to the prior year. For the fiscal-year ending December 31, 2014, the company expects total revenue in the range of approximately $4.7 million to $5.0 million, representing growth of approximately 160% to 180% year-over-year. Revenue from proprietary products is expected in the range of approximately $1.3 million to $1.6 million in the fourth quarter of 2014, representing growth of approximately 30% to 60% sequentially. Revenue from contract manufacturing is expected in the range of approximately $250,000-$300,000 in the fourth quarter of fiscal 2014. For the fiscal-year ending December 31, 2015, the company expects total revenue in the range of approximately $11.0 million to $13.0 million.

Alliqua, Inc. to Report Q3, 2014 Results on Oct 30, 2014

Alliqua, Inc. announced that they will report Q3, 2014 results After-Market on Oct 30, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALQA:US $4.99 USD -0.08

ALQA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Coloplast A/S kr538.00 DKK +7.00
Covidien PLC $106.98 USD -1.09
Derma Sciences Inc $8.76 USD +0.12
Smith & Nephew PLC 1,186 GBp -4.00
View Industry Companies
 

Industry Analysis

ALQA

Industry Average

Valuation ALQA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.1x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLIQUA BIOMEDICAL INC, please visit alliqua.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.